BATF and acute myeloid leukemia: In the TCGA cohort of AML patients who received allo-HSCT, BATF demonstrated good prognostic predictive ability (AUC3year = 0.70) (Figure 3C), with high BATF expression associated with poorer survival (3-year OS: 27.27% vs. 56.41%, P = 0.016) (Figure 3C).